Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003–13
Heart, Lung and Circulation. 2018;27:S563 
Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013
Cancer Research and Treatment. 2018;50(3):757-767
A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis
Lung Cancer. 2013;82(3):461-468
190 Tolvaptan – cost effective treatment of SIADH in malignancies
Lung Cancer. 2013;79:S66
P-66 Trend of lung cancer in recent 5 years; Analysis as viewed from age, gender, pathological types, stage of disease, therapeutic modality, and prognosis
Lung Cancer. 2003;41:S107
O-12 The cost effectiveness (CE) and cost to medicare of gefitinib (Iressa; ZD1839) for the third-line treatment of non-small cell lung cancer (NSCLC): Can medicare afford the bill?
Lung Cancer. 2003;41:S7-S8
Cost analysis of lung cancer management in South Western Sydney
Journal of Medical Imaging and Radiation Oncology. 2012;56(2):235-241
O-281 Cost analysis of video-assisted thoracic surgery (VATS) versus thoracotomy: Critical review
Lung Cancer. 2003;41:S82
47P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?
Lung Cancer. 2013;80:S20-S21
Cost analysis of hospital treatment—two chemotherapic regimens for non-surgical non-small cell lung cancer
Lung Cancer. 1996;14(1):31-44